iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Reaches New 12-Month High – Here’s What Happened

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) shares hit a new 52-week high on Monday . The company traded as high as $86.28 and last traded at $86.0510, with a volume of 134653 shares traded. The stock had previously closed at $84.81.

iShares U.S. Pharmaceuticals ETF Stock Performance

The stock has a market capitalization of $692.62 million, a price-to-earnings ratio of 17.75 and a beta of 0.54. The company has a 50-day moving average of $78.90 and a 200-day moving average of $72.12.

Institutional Trading of iShares U.S. Pharmaceuticals ETF

A number of large investors have recently made changes to their positions in IHE. BNP Paribas Financial Markets purchased a new position in iShares U.S. Pharmaceuticals ETF in the 2nd quarter worth approximately $13,108,000. JPMorgan Chase & Co. increased its position in shares of iShares U.S. Pharmaceuticals ETF by 781.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 110,936 shares of the company’s stock worth $7,271,000 after purchasing an additional 98,352 shares during the last quarter. Grimes & Company Inc. bought a new position in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth about $1,468,000. Ameriprise Financial Inc. grew its stake in iShares U.S. Pharmaceuticals ETF by 491.9% in the second quarter. Ameriprise Financial Inc. now owns 23,658 shares of the company’s stock worth $1,550,000 after purchasing an additional 19,661 shares in the last quarter. Finally, Boothe Investment Group Inc. bought a new stake in iShares U.S. Pharmaceuticals ETF in the second quarter valued at about $602,000.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.